Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M Voorhees,Cesar Rodriguez,Brandi Reeves,Nitya Nathwani,Luciano J Costa,Yana Lutska,Daniela Hoehn,Huiling Pei,Jon Ukropec,Ming Qi,Thomas Lin,Paul Richardson

doi:10.1182/blood-2018-151

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M Voorhees, Cesar Rodriguez + Show 10 more

Open Access

https://doi.org/10.1182/blood-2018-151

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 35

Affiliation: Janssen (United States), Levine Cancer Institute, University of Alabama at Birmingham, Dana-Farber Cancer Institute, Wake Forest University, City of Hope, Janssen (Belgium), University of North Carolina at Chapel Hill

#Minimal Residual Disease Negativity #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Full Text